Prev Close | 1.36 |
Open | 1.34 |
Day Low/High | 1.26 / 1.34 |
52 Wk Low/High | 0.21 / 1.57 |
Volume | 2.89M |
Prev Close | 1.36 |
Open | 1.34 |
Day Low/High | 1.26 / 1.34 |
52 Wk Low/High | 0.21 / 1.57 |
Volume | 2.89M |
Exchange | NASDAQ |
Shares Outstanding | 141.51B |
Market Cap | 185.38M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
With a pair of Phase III trials coming up for its dermatological drug, Novan CEO Nate Stasko says the company is merely piercing the skin of its long-term potential.